Connect with others who understand.

Sign up Log in
Resources
About MyMyelomaTeam
Powered By
See answer

Relapsed/Refractory Myeloma: Life Expectancy

Medically reviewed by Danielle Leonardo, M.D.
Written by Emily Wagner, M.S.
Updated on August 1, 2024

If you’ve been diagnosed with relapsed/refractory multiple myeloma (RRMM), you’re likely wondering what your future holds. It can be scary and overwhelming to hear your cancer has returned or isn’t responding to treatment, but you and your oncologist will work together to determine your next steps forward. There are more treatment options available now than ever before.

This article will cover how RRMM affects your life expectancy and what other factors may play a role. We’ll also cover what you can do to potentially improve your prognosis or outlook and stay as healthy as possible living with RRMM.

What Is Relapsed/Refractory Myeloma?

Multiple myeloma is a type of blood cancer that affects your white blood cells. Specifically, it causes your plasma cells — the cells responsible for making immune system proteins known as antibodies — to grow out of control. Plasma cells grow in the bone marrow (spongy tissue in your bones). When plasma cells grow too fast, they stop your bone marrow from making new, healthy blood cells.

Once you’re diagnosed with myeloma, your oncologist will create a treatment plan for you. Most treatment plans involve a combination of:

  • Chemotherapy drugs
  • Immunomodulatory imide drugs (IMiDs)
  • Proteasome inhibitors
  • Corticosteroids

One example of this treatment regimen is bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone. Your oncologist may substitute thalidomide (Thalomid) for lenalidomide. The goal of combination treatment is to kill off as many myeloma cells as possible.

Over 90 percent of people respond well to their first round of myeloma treatment. On average, people are disease-free (in remission) for about four years after their first treatment. Eventually, most people relapse and see their myeloma return. However, one study found that 16 percent of people developed relapsed myeloma within one year of starting treatment. If the disease returns, new therapies are considered.

“Refractory myeloma” is the term for when cancer doesn’t respond to treatment, or it starts progressing within two months of your last treatment. Your oncologist will have you try different treatment options to find one that works best for your cancer. If you respond initially to one treatment and then your myeloma returns and is resistant to other treatments, you’ll be diagnosed with relapsed/refractory multiple myeloma.

What Does Research Show About Life Expectancy With RRMM?

When talking about life expectancy with a certain type of cancer, doctors and researchers use the term “median overall survival.” If researchers were studying a group of people with cancer who had all been diagnosed at the same time (or started a certain treatment at the same time), median overall survival is the length of time after which half of the people in the group are still alive. Noting this time can help researchers better understand which treatments are helpful.

Many studies have reported different life expectancies and survival rates for people with RRMM. One study of nearly 13,000 people with RRMM found that the median overall survival after starting the second round of treatment was 32.4 months. This means half of the people in the study lived longer than 32.4 months.

In one study of nearly 13,000 people with relapsed/refractory multiple myeloma, half were still alive 32.4 months after beginning their second round of treatment.

Recent advances in treatment have helped people with RRMM live longer than before. One study found that bortezomib and lenalidomide given in combination with dexamethasone add an additional 1.7 years of life expectancy for those with RRMM, compared to those who did not have access to these treatments. The same study showed newer treatments like the monoclonal antibody drugs daratumumab (Darzalex) and elotuzumab (Empliciti) have increased life expectancy by 2.5 years.

Isatuximab (Sarclisa) is another approved monoclonal antibody for relapsed multiple myeloma, which is often used in combination with other therapies.

What Affects Life Expectancy and Prognosis With RRMM?

Several factors can affect your life expectancy with RRMM. Some of these are within your control, while others aren’t. Here, we’ll discuss how the different characteristics of myeloma, your age, and your overall health play a role in your prognosis (or outlook) with RRMM.

Time Until Relapse

Researchers have found that the time it takes for your cancer to return after treatment affects your prognosis. The sooner myeloma relapses after treatment, the worse your outlook is. On the other hand, the longer it takes for myeloma to return, the better your outlook is.

One study of 511 people with myeloma found that those whose myeloma returned within one year of starting treatment (early relapse) had a median overall survival of 21 months. This means that half of the people with early relapsed myeloma lived for more than 21 months.

People whose multiple myeloma relapses early — within one year of starting initial treatment — generally have a worse outlook than those whose cancer relapses later.

On the other hand, people whose cancer returned more than one year after treatment or those who were still responding to treatment (known as late relapse) didn’t reach a median overall survival after 10 years. This means that more than half of people in the study with late relapse were still alive after 10 years.

Cytogenetic Testing Results

The specific gene changes in your myeloma cells can affect your life expectancy and outlook. Known as high-risk cytogenetic features, these changes impact how well your RRMM responds to certain therapies.

A few studies have found that people with RRMM and these high-risk features tend to have shorter median overall survival. This is because certain mutations make your cancer more resistant to treatment. Your oncologist may test for these features and use them to create your treatment plan.

Age and Underlying Health Conditions

Myeloma is a cancer that tends to affect older adults — the average age at diagnosis is 70 years. Researchers have looked at how age and the greater likelihood of having underlying health conditions can affect your outlook with RRMM. Studies have found that people who are older and have more health conditions tend to have a worse myeloma treatment outlook.

Race, Ethnicity, and Life Expectancy

Race and ethnicity can also be factors that affect prognosis. Although survival has improved for people with multiple myeloma overall, survival rates for Black people with myeloma in the U.S. have not improved as much as survival rates for white people. Researchers have found that this is likely due to less access to treatment. Black and Hispanic people are less likely to have bone marrow transplants than white people. They’re also extremely underrepresented in clinical trials studying new treatments for multiple myeloma, compared with white and Asian people.

When everyone has equal access to care, Black and Hispanic people have similar or better survival rates than white people. To make sure you get access to the most effective treatment options for you, stay engaged with your health care team. Don’t hesitate to ask questions, and make sure your oncology team understands your goals for treatment.

Improving Your Outlook With RRMM

While some factors are out of your control, you can take steps to improve your quality of life and outlook living with RRMM. Be sure to stick closely to your cancer treatment plan. Your oncologist will go over the best treatment options for you, depending on your overall health, previous treatments, and test results.

Treatment options for RRMM include:

  • Immunotherapy with chimeric antigen receptor T-cell therapy (CAR T-cell therapy) using such options as idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti)
  • Proteasome inhibitors like carfilzomib (Kyprolis) and ixazomib (Ninlaro)
  • IMiDs like pomalidomide (Pomalyst)
  • Bispecific T-cell engagers like teclistamab-cqyv (Tecvayli), which was approved by the U.S. Food and Drug Administration (FDA) in 2022, and talquetamab (Talvey), which the FDA approved in 2023
  • Elranatamab-bcmm (Elrexfio), a bispecific antibody the FDA approved in 2023

Newer treatment options are adding months or years to life expectancy for many people with RRMM.

It’s important to take care of your body while living with RRMM and going through intense cancer treatments. Studies have found people with myeloma tend to have a lower health-related quality of life compared to people with most other types of cancer. Many people get tired easily or have trouble breathing or chronic pain, which can make it hard to be active. Talk to your oncologist about whether adding some light exercise to your routine would be helpful for you. They can make recommendations for activities that are best for your overall health.

Talk With Others Who Understand

MyMyelomaTeam is the social network for people with multiple myeloma and their loved ones. On MyMyelomaTeam, more than 25,000 members come together to ask questions, give advice, and share their stories with others who understand life with myeloma.

Do you have more questions about life expectancy with relapsed/refractory myeloma? Share your thoughts in the comments below, or start a conversation by posting on your Activities page.

References
  1. What Is Multiple Myeloma? — American Cancer Society
  2. Multiple Myeloma: Initial Treatment — Wolters Kluwer UpToDate
  3. Frontline Myeloma Treatment Options — International Myeloma Foundation
  4. The Future Looks Bright — Including a Cure for Myeloma — International Myeloma Foundation
  5. Treatment Outcomes — Leukemia & Lymphoma Society
  6. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond — Cancers
  7. Early Relapse Following Initial Therapy for Multiple Myeloma Predicts Poor Outcomes in the Era of Novel Agents — Leukemia
  8. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse — Current Oncology
  9. Median Survival — National Cancer Institute
  10. Survival and Treatment Patterns of Patients With Relapsed or Refractory Multiple Myeloma in France — A Cohort Study Using the French National Healthcare Database (SNDS) — Annals of Hematology
  11. The Value of Survival Gains From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology
  12. Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology
  13. FDA D.I.S.C.O. Burst Edition: FDA Approvals of Talvey (Talquetamab-tgvs) for Relapsed or Refractory Multiple Myeloma, and Elrexfio (Elranatamab-bcmm) for Relapsed or Refractory Multiple Myeloma — U.S. Food and Drug Administration
  14. FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma — U.S. Food and Drug Administration
  15. Cytogenetics and Long-Term Survival of Patients With Refractory or Relapsed and Refractory Multiple Myeloma Treated With Pomalidomide and Low-Dose Dexamethasone — Haematologica
  16. Frailty in Relapsed/Refractory Multiple Myeloma Registration Trials — Journal of Clinical Oncology
  17. Clinical Impact of Frailty on Treatment Outcomes of Elderly Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Lenalidomide Plus Dexamethasone — International Journal of Hematology
  18. Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma — Clinical Lymphoma, Myeloma & Leukemia
  19. An Individualized Exercise Intervention for People With Multiple Myeloma — Study Protocol of a Randomized Waitlist-Controlled Trial — Current Oncology
  20. Lifestyle Considerations in Multiple Myeloma — Blood Cancer Journal

Updated on August 1, 2024

A MyMyelomaTeam Member

Gwdstib, I too post that I am shocked w/ the poor quality of these articles, and I am glad to see that I am not the only one. However, in this case RRMM is a correct term. MM is incurable, but each… read more

October 16
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy

My Husband Just Went On Hospice. What Does The End Stage Of MM Look Like?

October 22, 2023 by A MyMyelomaTeam Member 4 answers

What Treatment Works When The Car-tcell Procedure Relapses?

January 25, 2024 by A MyMyelomaTeam Member 2 answers
Danielle Leonardo, M.D. is a board-certified specialist in internal medicine and medical oncology from the Philippines and has been practicing medicine since 2014. Learn more about her here.
Emily Wagner, M.S. holds a Master of Science in biomedical sciences with a focus in pharmacology. She is passionate about immunology, cancer biology, and molecular biology. Learn more about her here.

Related Articles

Multiple myeloma is a type of blood cancer that affects plasma cells. Plasma cells are white bloo...

Stage 2 Multiple Myeloma Prognosis: Fear, Hope, and Understanding Survival Rates

Multiple myeloma is a type of blood cancer that affects plasma cells. Plasma cells are white bloo...
A variety of tests play a role in diagnosing multiple myeloma, including serum protein electropho...

Understanding Serum Protein Electrophoresis (SPEP) for Multiple Myeloma

A variety of tests play a role in diagnosing multiple myeloma, including serum protein electropho...
A diagnosis of multiple myeloma can feel overwhelming, but understanding the process can help you...

Multiple Myeloma – The Path to Diagnosis

A diagnosis of multiple myeloma can feel overwhelming, but understanding the process can help you...
Multiple myeloma is a kind of cancer that develops when white blood cells called lymphocytes beco...

Multiple Myeloma Types and Related Conditions

Multiple myeloma is a kind of cancer that develops when white blood cells called lymphocytes beco...
Multiple myeloma occurs when certain white blood cells, called plasma cells, become abnormal and ...

Stage 1 Multiple Myeloma: What To Expect

Multiple myeloma occurs when certain white blood cells, called plasma cells, become abnormal and ...
Multiple myeloma is a type of blood cancer that develops when white blood cells called plasma cel...

Multiple Myeloma – An Overview

Multiple myeloma is a type of blood cancer that develops when white blood cells called plasma cel...

Recent Articles

Back pain is a common and challenging symptom of myeloma and is often one of the first symptoms t...

Back Pain and Myeloma: What It Feels Like

Back pain is a common and challenging symptom of myeloma and is often one of the first symptoms t...
4 Ways To Reduce the Cost of Medication The price of medication affects the quality of life f...

4 Ways To Reduce the Cost of Medication (VIDEO)

4 Ways To Reduce the Cost of Medication The price of medication affects the quality of life f...
This fall and winter, the Centers for Disease Control and Prevention (CDC) expects the number of ...

3 Layers of COVID-19 Protection: New Vaccines, Prevention Drug, and Tests

This fall and winter, the Centers for Disease Control and Prevention (CDC) expects the number of ...
In the past 20 years, clinical research studies have led to new treatments for blood cancers such...

Are We Close to a Cure for Blood Cancer? Dr. Nowakowski Weighs In

In the past 20 years, clinical research studies have led to new treatments for blood cancers such...
Light chain multiple myeloma is a type of multiple myeloma, a cancer of the plasma cells.

Light Chain Multiple Myeloma: Symptoms, Life Expectancy, and More

Light chain multiple myeloma is a type of multiple myeloma, a cancer of the plasma cells.
Multiple myeloma, like all cancers, begins with genetic mutations that disrupt the normal process...

What Causes Multiple Myeloma?

Multiple myeloma, like all cancers, begins with genetic mutations that disrupt the normal process...

Thank you for subscribing!

Become a member to get even more: